This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hosie, M. J.
Right arrow Articles by Neil, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hosie, M. J.
Right arrow Articles by Neil, J. C.

 Previous Article  |  Next Article 

Journal of Virology, October 2000, p. 9403-9411, Vol. 74, No. 20
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Vaccination with Inactivated Virus but Not Viral DNA Reduces Virus Load following Challenge with a Heterologous and Virulent Isolate of Feline Immunodeficiency Virus

Margaret J. Hosie,1,* Thomas Dunsford,1 Dieter Klein,2 Brian J. Willett,1 Celia Cannon,1 Robert Osborne,1 Julie MacDonald,1 Norman Spibey,1,dagger Nancy Mackay,1 Oswald Jarrett,1 and James C. Neil1

Department of Veterinary Pathology, University of Glasgow Veterinary School, Glasgow G61 1QH, United Kingdom,1 and Institute of Virology, University of Veterinary Medicine, A-1210 Vienna, Austria2

Received 15 May 2000/Accepted 24 July 2000

It has been shown that cats can be protected against infection with the prototypic Petaluma strain of feline immunodeficiency virus (FIVPET) using vaccines based on either inactivated virus particles or replication-defective proviral DNA. However, the utility of such vaccines in the field is uncertain, given the absence of consistent protection against antigenically distinct strains and the concern that the Petaluma strain may be an unrepresentative, attenuated isolate. Since reduction of viral pathogenicity and dissemination may be useful outcomes of vaccination, even in the absence of complete protection, we tested whether either of these vaccine strategies ameliorates the early course of infection following challenge with heterologous and more virulent isolates. We now report that an inactivated virus vaccine, which generates high levels of virus neutralizing antibodies, confers reduced virus loads following challenge with two heterologous isolates, FIVAM6 and FIVGL8. This vaccine also prevented the marked early decline in CD4/CD8 ratio seen in FIVGL8-infected cats. In contrast, DNA vaccines based on either FIVPET or FIVGL8, which induce cell-mediated responses but no detectable antiviral antibodies, protected a fraction of cats against infection with FIVPET but had no measurable effect on virus load when the infecting virus was FIVGL8. These results indicate that the more virulent FIVGL8 is intrinsically more resistant to vaccinal immunity than the FIVPET strain and that a broad spectrum of responses which includes virus neutralizing antibodies is a desirable goal for lentivirus vaccine development.


* Corresponding author. Mailing address: Department of Veterinary Pathology, University of Glasgow Veterinary School, Bearsden Rd., Glasgow G61 1QH, United Kingdom. Phone: 44 41 330 3274. Fax: 44 141 330 5602. E-mail: m.hosie{at}vet.gla.ac.uk.

dagger Present address: Intervet UK Ltd., St. Ives, Cambs PE17 2BQ, United Kingdom.


Journal of Virology, October 2000, p. 9403-9411, Vol. 74, No. 20
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • VandeWoude, S., Apetrei, C. (2006). Going Wild: Lessons from Naturally Occurring T-Lymphotropic Lentiviruses. Clin. Microbiol. Rev. 19: 728-762 [Abstract] [Full Text]  
  • Pistello, M., Bonci, F., Flynn, J. N., Mazzetti, P., Isola, P., Zabogli, E., Camerini, V., Matteucci, D., Freer, G., Pelosi, P., Bendinelli, M. (2006). AIDS Vaccination Studies with an Ex Vivo Feline Immunodeficiency Virus Model: Analysis of the Accessory ORF-A Protein and DNA as Protective Immunogens.. J. Virol. 80: 8856-8868 [Abstract] [Full Text]  
  • Broche-Pierre, S., Richardson, J., Moraillon, A., Sonigo, P. (2005). Evaluation of live feline immunodeficiency virus vaccines with modified antigenic properties. J. Gen. Virol. 86: 2495-2506 [Abstract] [Full Text]  
  • Flynn, J. N., Pistello, M., Isola, P., Zaccaro, L., Del Santo, B., Ricci, E., Matteucci, D., Bendinelli, M. (2005). Adoptive Immunotherapy of Feline Immunodeficiency Virus with Autologous Ex Vivo-Stimulated Lymphoid Cells Modulates Virus and T-Cell Subsets in Blood. CVI 12: 736-745 [Abstract] [Full Text]  
  • Hosie, M. J., Klein, D., Binley, J. M., Dunsford, T. H., Jarrett, O., Neil, J. C., Knapp, E., Giannecchini, S., Matteucci, D., Bendinelli, M., Hoxie, J. A., Willett, B. J. (2005). Vaccination with an Inactivated Virulent Feline Immunodeficiency Virus Engineered To Express High Levels of Env. J. Virol. 79: 1954-1957 [Abstract] [Full Text]  
  • Pistello, M., Matteucci, D., Bonci, F., Isola, P., Mazzetti, P., Zaccaro, L., Merico, A., Del Mauro, D., Flynn, N., Bendinelli, M. (2003). AIDS Vaccination Studies Using an Ex Vivo Feline Immunodeficiency Virus Model: Protection from an Intraclade Challenge Administered Systemically or Mucosally by an Attenuated Vaccine. J. Virol. 77: 10740-10750 [Abstract] [Full Text]  
  • Ryan, G., Klein, D., Knapp, E., Hosie, M. J., Grimes, T., Mabruk, M. J. E. M. F., Jarrett, O., Callanan, J. J. (2003). Dynamics of Viral and Proviral Loads of Feline Immunodeficiency Virus within the Feline Central Nervous System during the Acute Phase following Intravenous Infection. J. Virol. 77: 7477-7485 [Abstract] [Full Text]  
  • Hosie, M. J., Willett, B. J., Klein, D., Dunsford, T. H., Cannon, C., Shimojima, M., Neil, J. C., Jarrett, O. (2002). Evolution of Replication Efficiency following Infection with a Molecularly Cloned Feline Immunodeficiency Virus of Low Virulence. J. Virol. 76: 6062-6072 [Abstract] [Full Text]  
  • Giannecchini, S., Matteucci, D., Ferrari, A., Pistello, M., Bendinelli, M. (2001). Feline Immunodeficiency Virus-Infected Cat Sera Associated with the Development of Broad Neutralization Resistance In Vivo Drive Similar Reversions In Vitro. J. Virol. 75: 8868-8873 [Abstract] [Full Text]  
  • Giannecchini, S., Del Mauro, D., Matteucci, D., Bendinelli, M. (2001). AIDS Vaccination Studies Using an Ex Vivo Feline Immunodeficiency Virus Model: Reevaluation of Neutralizing Antibody Levels Elicited by a Protective and a Nonprotective Vaccine after Removal of Antisubstrate Cell Antibodies. J. Virol. 75: 4424-4429 [Abstract] [Full Text]